ADC Therapeutics SA - 10-Q Filing
ADC Therapeutics SA reports Q3 2026 financial results including revenue components and restructuring activity.
Tickers: $ADCT
Read the full article at SEC EDGAR
Part of the story FMC Reports Significant Third Quarter Losses Driven by Pricing Restructuring and Inventory Adjustments (5 articles)